Metabolomics of renal venous plasma from individuals with unilateral renal artery stenosis and essential hypertension

Objective: To compare the metabolite profiles of venous effluent from both kidneys of individuals with unilateral atherosclerotic renal artery stenosis (ARAS) in order to directly examine how impaired renal blood flow impacts small-molecule handling in humans. Methods: We applied liquid chromatography–mass spectrometry based metabolite profiling to venous plasma obtained from the stenotic (STK) and contralateral (CLK) kidneys of ARAS patients (n = 16), and both the kidneys of essential hypertensive controls (n = 11). Study samples were acquired during a 3-day protocol that included iothalamate clearance measurements, radiographic kidney phenotyping (Duplex ultrasound, multidetector computed tomography, and blood-oxygen-level-dependent MRI), and controlled sodium and caloric intake and antihypertensive treatment. Results: Partial least squares-discriminant analysis demonstrated clear separation of essential hypertensive kidney metabolite profiles versus STK and CLK metabolite profiles, but no separation between metabolite profiles of STK and CLK samples. All of the discriminating metabolites were similarly elevated in the STK and CLK samples, likely reflecting the lower glomerular filtration rate in the ARAS versus essential hypertensive individuals (mean 66.1 versus 89.2 ml/min per 1.73 m2). In a paired analysis within the ARAS group, no metabolite was significantly altered in STK compared with CLK samples; notably, creatinine was the same in STK and CLK samples (STK/CLK ratio = 1.0, P = 0.9). Results were unchanged in an examination of ARAS patients in the bottom half of renal tissue perfusion or oxygenation. Conclusion: Metabolite profiling does not differentiate venous effluent from STKs or CLKs in individuals with unilateral ARAS, despite the measurable loss of kidney volume and blood flow on the affected side. These findings are consistent with the kidney's ability to adapt to ARAS to maintain a range of metabolic functions.

[1]  Steven D. Hochman,et al.  Revascularization versus Medical Therapy for Renal Artery Stenosis , 2015 .

[2]  H. Mischak,et al.  Plasma and urinary amino acid metabolomic profiling in patients with different levels of kidney function. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[3]  T. Meyer,et al.  Uremic solutes and risk of end stage renal disease in type 2 diabetes , 2014, Kidney international.

[4]  Ralph B D'Agostino,et al.  Stenting and medical therapy for atherosclerotic renal-artery stenosis. , 2014, The New England journal of medicine.

[5]  R. Gerszten,et al.  A Plasma Long‐Chain Acylcarnitine Predicts Cardiovascular Mortality in Incident Dialysis Patients , 2013, Journal of the American Heart Association.

[6]  T. Ideker,et al.  Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. , 2013, Journal of the American Society of Nephrology : JASN.

[7]  R. Vasan,et al.  A combined epidemiologic and metabolomic approach improves CKD prediction. , 2013, Journal of the American Society of Nephrology : JASN.

[8]  Christian Gieger,et al.  Metabolites associate with kidney function decline and incident chronic kidney disease in the general population. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[9]  Ming-Huei Chen,et al.  A genome-wide association study of the human metabolome in a community-based cohort. , 2013, Cell metabolism.

[10]  Harold I Feldman,et al.  Plasma metabolomic profiles in different stages of CKD. , 2013, Clinical journal of the American Society of Nephrology : CJASN.

[11]  L. Lerman,et al.  Inflammatory and injury signals released from the post-stenotic human kidney. , 2013, European heart journal.

[12]  C. Gieger,et al.  Serum metabolite concentrations and decreased GFR in the general population. , 2012, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  Raymond Vanholder,et al.  Normal and pathologic concentrations of uremic toxins. , 2012, Journal of the American Society of Nephrology : JASN.

[14]  David S. Wishart,et al.  MetaboAnalyst 2.0—a comprehensive server for metabolomic data analysis , 2012, Nucleic Acids Res..

[15]  L. Lerman,et al.  Blood Oxygen Level–Dependent Magnetic Resonance Imaging Identifies Cortical Hypoxia in Severe Renovascular Disease , 2011, Hypertension.

[16]  Fabian J Theis,et al.  Discovery of Sexual Dimorphisms in Metabolic and Genetic Biomarkers , 2011, PLoS genetics.

[17]  S. Carr,et al.  Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. , 2011, The Journal of clinical investigation.

[18]  V. Mootha,et al.  Metabolite profiles and the risk of developing diabetes , 2011, Nature Medicine.

[19]  M. Kohno,et al.  Metabolomic analysis of human plasma from haemodialysis patients , 2011, European journal of clinical investigation.

[20]  K. Bailey,et al.  Ischaemic nephropathy secondary to atherosclerotic renal artery stenosis: clinical and histopathological correlates. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[21]  E. Mishima,et al.  Metabolomic profiling of uremic solutes in CKD patients , 2010, Hypertension Research.

[22]  R. Gerszten,et al.  Metabolite profiling identifies markers of uremia. , 2010, Journal of the American Society of Nephrology : JASN.

[23]  L. Lerman,et al.  Preserved Oxygenation Despite Reduced Blood Flow in Poststenotic Kidneys in Human Atherosclerotic Renal Artery Stenosis , 2010, Hypertension.

[24]  R. Carey.  Are kidneys not ischemic in human renal vascular disease? , 2010, Hypertension.

[25]  L. Lerman,et al.  Comparison of 1.5 and 3 T BOLD MR to Study Oxygenation of Kidney Cortex and Medulla in Human Renovascular Disease , 2009, Investigative radiology.

[26]  G. Garibotto,et al.  The kidney is the major site of S-adenosylhomocysteine disposal in humans. , 2009, Kidney international.

[27]  David S. Wishart,et al.  MetaboAnalyst: a web server for metabolomic data analysis and interpretation , 2009, Nucleic Acids Res..

[28]  T. Zeller.  Renal artery stenosis , 2007, Current treatment options in cardiovascular medicine.

[29]  S. Textor,et al.  Renal artery stenosis: a common, treatable cause of renal failure? , 2001, Annual review of medicine.

[30]  R. Zierler,et al.  Clinical Evidence of Contralateral Renal Parenchymal Injury in Patients with Unilateral Atherosclerotic Renal Artery Stenosis , 1998, Annals of vascular surgery.

[31]  F. Luft,et al.  Early interstitial changes in hypertension-induced renal injury. , 1993, Hypertension.

[32]  J. Henriksen,et al.  Renal vein oxygen saturation in renal artery stenosis. , 1992, Clinical physiology.

[33]  G. Garibotto,et al.  Renal metabolism of amino acids and ammonia in subjects with normal renal function and in patients with chronic renal insufficiency. , 1980, The Journal of clinical investigation.

[34]  R. R. Robinson,et al.  Amino acid extraction and ammonia metabolism by the human kidney during the prolonged administration of ammonium chloride. , 1963, The Journal of clinical investigation.